Microsoft opened its 2014 Super Bowl ad with the question: “What is technology?” As Steve Gleason, an ex-New Orleans Saints safety later diagnosed with amyotrophic lateral sclerosis (ALS), spoke about the power of technology, videos rolled of doctors manipulating 3D X-rays, a blind man painting,…
Former NFL Player, Microsoft Team Up to Make Technology More Accessible
Columns
The Burden of Knowing the Future
Lulu Wang’s film “The Farewell” is based on an actual lie. The 2019 comedic drama looks at a family’s decision to keep their matriarch ignorant of her stage IV lung cancer diagnosis with a prognosis of death in three months. Billi, a Chinese American woman, travels to China for…
IPL344, Immunity Pharma‘s investigational therapy for amyotrophic lateral sclerosis (ALS), has a positive safety and tolerability profile and slows disease progression by about 50%, according to interim results from a small Phase 1/2a clinical trial. The company said it now is planning a placebo-controlled trial to evaluate IPL344…
The first patient has been dosed in a Phase 2a clinical trial evaluating the safety and effectiveness of ALZT-OP1a, a dry-powder inhaled formulation of cromolyn, in people with mild-to-moderate amyotrophic lateral sclerosis (ALS). The trial (NCT04428775) is recruiting up to 80 patients, ages 18–75, who have been…
Big news buzzed through the ALS community last week about AMX0035, an investigational treatment for ALS that just finished a Phase 2/3 clinical trial. Early results indicated that AMX0035 slowed the progression of ALS symptoms. Although discovering a cure for ALS is still the ultimate goal for…
Helixmith has selected Worldwide Clinical Trials to run a planned Phase 2 study of Engensis (VM202), its potential gene therapy for amyotrophic lateral sclerosis (ALS), according to a company press release. Engensis consists of a circular piece of DNA called a plasmid that carries instructions…
PrimeC is safe and well-tolerated for the treatment of amyotrophic lateral sclerosis (ALS) and shows potential to slow disease progression and lung function decline, according to interim results from a Phase 2a clinical trial. Given these results, developer NeuroSense Therapeutics will continue investigating PrimeC with additional analysis…
Newly developed compounds derived from ebselen could be used to treat some types of amyotrophic lateral sclerosis (ALS), a recent study suggests. The study, “Novel Selenium-based compounds with therapeutic potential for SOD1-linked amyotrophic lateral sclerosis,” was published in EBioMedicine. About a fifth of familial…
Perspective can be hard to come by with ALS, but writing has helped me keep my head above water. I’ve kept a journal since I was a kid. I wrote my way through teenage angst, my musings during my college years, the challenges of trying to help the teens I…
Patient enrollment is now complete for the Phase 2 clinical trial of Clene Nanomedicine‘s CNM-Au8 as a potentially disease-modifying therapy for amyotrophic lateral sclerosis (ALS). The trial, named RESCUE-ALS (NCT04098406) will test the safety, efficacy, pharmacokinetics, and pharmacodynamics —…
Recent Posts
- Scientists find promising 3 drug combo for sporadic ALS using new models
- Small adjustments to a wheelchair can greatly improve comfort
- How ALS patients can show their stripes for Rare Disease Month
- Grants support next generation of ALS researchers in Canada
- ALS research wins big bucks with $313M in new US government funding